Atara Biotherapeutics, Inc. (LON:0HIY)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 93.62M |
| Revenue (ttm) | 113.03M |
| Net Income (ttm) | 17.41M |
| Shares Out | n/a |
| EPS (ttm) | 1.46 |
| PE Ratio | 5.38 |
| Forward PE | 10.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63 |
| Average Volume | 3,707 |
| Open | 17.81 |
| Previous Close | 15.01 |
| Day's Range | 17.81 - 17.81 |
| 52-Week Range | 5.00 - 19.05 |
| Beta | n/a |
| RSI | 54.31 |
| Earnings Date | Feb 6, 2026 |
About Atara Biotherapeutics
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queenslan... [Read more]
Financial Performance
In 2024, Atara Biotherapeutics's revenue was $128.94 million, an increase of 1404.02% compared to the previous year's $8.57 million. Losses were -$85.40 million, -69.07% less than in 2023.
Financial numbers in USD Financial StatementsNews
Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canaccord Genuity | ATRA Stock News
Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canaccord Genuity | ATRA Stock News
Atara Biotherapeutics: An Empty Pipeline With Little Gas
Atara nears an FDA-backed cell therapy milestone with no commercialization rights and a suspended pipeline offering few catalysts. Learn why ATRA stock is a sell.
Atara Biotherapeutics (ATRA) Reduces Workforce by 29% in Strategic Move
Atara Biotherapeutics (ATRA) Reduces Workforce by 29% in Strategic Move
Atara Biotherapeutics (ATRA) Exceeds Q3 Revenue Estimates
Atara Biotherapeutics (ATRA) Exceeds Q3 Revenue Estimates
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...
Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pierre Fabre
Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pierre Fabre
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDU...
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. Spotlight On 4 Biotech Stocks...
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...
Atara Biotherapeutics Announces Changes to Its Board of Directors
THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop...
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+...
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) inves...
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics GAAP EPS of $3.50, revenue of $98.15M
Atara Biotherapeutics prices $16M public offering
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Announces Pricing of $16 Million Offering
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics to reduce workforce by 30%
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl...